These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 17665040)

  • 1. p53 immunostaining is correlated with reduced survival and is not correlated with gene mutations in resected pulmonary large cell carcinomas.
    Massoni Neto LM; Bianchi CP; Ab'Saber AM; Parra ER; Takagaki T; Pereira JC; Soares FA; Leite K; Capelozzi VL
    Braz J Med Biol Res; 2007 Aug; 40(8):1045-53. PubMed ID: 17665040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile.
    Hermans BCM; Derks JL; Thunnissen E; van Suylen RJ; den Bakker MA; Groen HJM; Smit EF; Damhuis RA; van den Broek EC; ; Ruland A; Speel EJM; Dingemans AMC
    Lung Cancer; 2019 Dec; 138():102-108. PubMed ID: 31678831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871.
    Carbone DP; Mitsudomi T; Chiba I; Piantadosi S; Rusch V; Nowak JA; McIntire D; Slamon D; Gazdar A; Minna J
    Chest; 1994 Dec; 106(6 Suppl):377S-381S. PubMed ID: 7988268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment outcomes of patients with different subtypes of large cell carcinoma of the lung.
    Sun YH; Lin SW; Hsieh CC; Yeh YC; Tu CC; Chen KJ
    Ann Thorac Surg; 2014 Sep; 98(3):1013-9. PubMed ID: 25085555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between p53 mutation and clinicopathological features of non-small cell lung cancer.
    Guang SG; Ogura T; Sekine I; Yokozaki M; Esumi H; Kodama T; Nagai K
    Jpn J Clin Oncol; 1997 Aug; 27(4):211-5. PubMed ID: 9379505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic alterations in early-stage pulmonary large cell neuroendocrine carcinoma.
    Hiroshima K; Iyoda A; Shibuya K; Haga Y; Toyozaki T; Iizasa T; Nakayama T; Fujisawa T; Ohwada H
    Cancer; 2004 Mar; 100(6):1190-8. PubMed ID: 15022286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer.
    Huang CL; Taki T; Adachi M; Konishi T; Higashiyama M; Kinoshita M; Hadama T; Miyake M
    Int J Oncol; 1998 Mar; 12(3):553-63. PubMed ID: 9472092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
    Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
    Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 gene alteration in atypical epithelial lesions and carcinoma in patients with idiopathic pulmonary fibrosis.
    Kawasaki H; Ogura T; Yokose T; Nagai K; Nishiwaki Y; Esumi H
    Hum Pathol; 2001 Oct; 32(10):1043-9. PubMed ID: 11679937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P63 expression in lung carcinoma: a tissue microarray study of 408 cases.
    Au NH; Gown AM; Cheang M; Huntsman D; Yorida E; Elliott WM; Flint J; English J; Gilks CB; Grimes HL
    Appl Immunohistochem Mol Morphol; 2004 Sep; 12(3):240-7. PubMed ID: 15551738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
    Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
    Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology.
    Ludovini V; Pistola L; Gregorc V; Floriani I; Rulli E; Piattoni S; Di Carlo L; Semeraro A; Darwish S; Tofanetti FR; Stocchi L; Mihaylova Z; Bellezza G; Del Sordo R; Daddi G; Crinò L; Tonato M
    J Thorac Oncol; 2008 Apr; 3(4):365-73. PubMed ID: 18379354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of K-ras, N-ras, H-ras, and p53 in lung neuroendocrine neoplasms.
    Couce ME; Bautista D; Costa J; Carter D
    Diagn Mol Pathol; 1999 Jun; 8(2):71-9. PubMed ID: 10475381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of loss of heterozygosity in large cell neuroendocrine carcinomas of the lung and small cell lung carcinomas.
    Takeuchi T; Minami Y; Iijima T; Kameya T; Asamura H; Noguchi M
    Pathol Int; 2006 Aug; 56(8):434-9. PubMed ID: 16872437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct clinicopathologic features, genomic characteristics and survival of central and peripheral pulmonary large cell neuroendocrine carcinoma: From different origin cells?
    Zhou F; Hou L; Ding T; Song Q; Chen X; Su C; Li W; Gao G; Ren S; Wu F; Fan J; Wu C; Zhang J; Zhou C
    Lung Cancer; 2018 Feb; 116():30-37. PubMed ID: 29413048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary large-cell neuroendocrine carcinoma of the parotid gland: immunohistochemical and molecular analysis of two cases.
    Nagao T; Sugano I; Ishida Y; Tajima Y; Munakata S; Asoh A; Yamazaki K; Muto H; Konno A; Kondo Y; Nagao K
    Mod Pathol; 2000 May; 13(5):554-61. PubMed ID: 10824928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroendocrine marker staining pattern categorization of small-sized pulmonary large cell neuroendocrine carcinoma.
    Minami K; Tanaka Y; Ogawa H; Jimbo N; Nishio W; Yoshimura M; Itoh T; Maniwa Y
    Thorac Cancer; 2019 Nov; 10(11):2152-2160. PubMed ID: 31583856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.
    Schiller JH; Adak S; Feins RH; Keller SM; Fry WA; Livingston RB; Hammond ME; Wolf B; Sabatini L; Jett J; Kohman L; Johnson DH
    J Clin Oncol; 2001 Jan; 19(2):448-57. PubMed ID: 11208838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of genomic landscapes of large cell neuroendocrine carcinoma, small cell lung carcinoma, and large cell carcinoma.
    Zhou Z; Zhu L; Niu X; Shen S; Zhao Y; Zhang J; Ye J; Han-Zhang H; Liu J; Liu C; Lu S
    Thorac Cancer; 2019 Apr; 10(4):839-847. PubMed ID: 30793508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.